Search Results

You are looking at 51 - 60 of 521 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

NCCN Task Force Report: Breast Cancer in the Older Woman

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709–1717. Breast Cancer Mortality Figure 3 shows age-specific breast cancer incidence rates in the United States from the SEER database for 1975 to 2003 for women aged 40

Full access

Complications of Radioactive Iodine Treatment of Thyroid Carcinoma

Stephanie L. Lee

Effects of 131 I Therapy RAI therapy is given either as remnant ablation (the most common use), adjuvant therapy, or treatment of metastatic disease. Remnant ablation uses RAI to destroy normal residual functioning thyroid tissues with the goals

Full access

Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

Biol Endocrinol 2011 ; 9 : 93 . 9. Eggemann H Ignatov A Smith BJ . Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients . Breast Cancer Res Treat 2013 ; 137 : 465 – 470 . 10

Full access

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

and 193). 1 – 5 However, for some patients with early-stage disease, surgery alone (followed by observation) may be sufficient as primary treatment. In addition, for certain histologic subtypes, adjuvant therapy with hormonal agents are options that

Full access

A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy

Lindsey M. Charo, Adam M. Burgoyne, Paul T. Fanta, Hitendra Patel, Juliann Chmielecki, Jason K. Sicklick, and Michael T. McHale

are generally managed surgically, and patients with tumors harboring high-risk features are recommended to receive adjuvant therapy with imatinib, a tyrosine kinase inhibitor that targets the KIT and PDGFRA oncoproteins, but not BRAF, NTRK3, or FGFR1

Full access

Fertility-Sparing Surgery in Early-Stage Cervical Cancer: Indications and Applications

Nadeem R. Abu-Rustum and Yukio Sonoda

-sparing adjuvant therapy in patients with node-positive disease. The authors' current selection criteria for fertility-sparing radical trachelectomy are listed in Table 1 . Patients are selected for a laparoscopic vaginal approach (Dargent operation) if they are

Full access

Changes in Prescribing Patterns in Stage III Colon Cancer

Fang-Shu Ou, Daniel J. Walden, Joseph J. Larson, Sandra Kang, Cassia R. Griswold, Benjamin E. Ueberroth, Bhamini Patel, Amber Draper, Puneet Raman, Olatunji B. Alese, Mohamad B. Sonbol, Tanios S. Bekaii-Saab, Christina S. Wu, and Daniel H. Ahn

noninferiority of 3 months of adjuvant therapy in the overall population, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer include the recommendation of 3 to 6 months of adjuvant chemotherapy based on risk stratification. 8

Full access

Geriatric Assessment in Older Patients with Breast Cancer

Heidi Klepin, Supriya Mohile, and Arti Hurria

/CTSU 49907 [abstract] . J Clin Oncol 2008 ; 26 ( Suppl 1 ): Abstract 507 . 31 Ravdin PM Siminoff LA Davis GJ . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19

Full access

Using NCCN Clinical Practice Guidelines in Oncology to Measure the Quality of Colorectal Cancer Care in the Veterans Health Administration

George L. Jackson, Leah L. Zullig, S. Yousuf Zafar, Adam A. Powell, Diana L. Ordin, Ziad F. Gellad, David Abbott, James M. Schlosser, Janis Hersh, and Dawn Provenzale

Cancers allowed the authors to create a system that could be used to examine quality across the spectrum of CRC care, from diagnosis through neoadjuvant therapy, surgery, adjuvant therapy, and surveillance or end-of-life care. The tool had important

Full access

BPI19-017: Clinical Pathway Toward Quality and Efficient Care of Breast Cancer in Women Under 50

Elizabeth Reed, Robin M. Lally, and Roksana Zak

unavailable (n=66). Eight clinical pathways based on ER, PR, and HER2 status were developed to guide treatment, considerations, evidence-based neoadjuvant and adjuvant therapy, and survivorship care. Pathways, with associated educational webinars and links to